Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03623464 · ClinicalTrials.gov registry record · NA
RCT of Mobile Apps & FitBit v. Usual Care
A NA study of Pancreatic Cancer and Gastric Cancer, sponsored by Weill Medical College of Cornell University.
- Active
- Registry status
- NA
- Development phase
- 107
- Enrollment target
- 1
- Study location
NCT03623464: Active NA study of Pancreatic Cancer and Gastric Cancer, sponsored by Weill Medical College of Cornell University.
NCT03623464 is a NA study of Pancreatic Cancer and Gastric Cancer that is active but no longer recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 107 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03623464, a NA study of Pancreatic Cancer and Gastric Cancer, is active but no longer recruiting, sponsored by Weill Medical College of Cornell University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 107 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized clinical trial to evaluate the use of mobile devices in preventing readmission in patients undergoing major GI cancer operations.
Primary Outcome
Investigators will track readmission rates after surgery for those on the trial
Conditions Studied
Interventions
- OTHER Standard of care
- OTHER Mobile health application and Fitbit + standard of care
Study Locations (1)
New York
- Weill Cornell Medicine- New York Presbyterian - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2017-05-31 |
| Est. Completion | 2026-06 |
| Phase | NA |
What the registry record for NCT03623464 still lists
NCT03623464 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (73% lower).
The record links to 6 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Standard of care is the first listed.
NCT03623464 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03623464 about?
NCT03623464 is a clinical study titled "RCT of Mobile Apps & FitBit v. Usual Care". This is a randomized clinical trial to evaluate the use of mobile devices in preventing readmission in patients undergoing major GI cancer operations.
What is the current status of trial NCT03623464?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 107 participants. The study started on 2017-05-31. Estimated completion is 2026-06.
What conditions does trial NCT03623464 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer, Hepatic Cancer.
What interventions are being tested in trial NCT03623464?
The interventions under investigation include: Standard of care (OTHER), Mobile health application and Fitbit + standard of care (OTHER).
Who is sponsoring clinical trial NCT03623464?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03623464 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03623464's enrollment target sits among peer trials
107 101st of 278 higher than 178 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
RECRUITING · NA
-
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
RECRUITING · NA
-
Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
RECRUITING · NA
-
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491668 · 107 participants
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI